Exact Sciences Stock News

Related Stocks: AMED , PLNT , VRM , BILL , AVLR , ETSY , RBLX , ALGN , EXAS , TER , MASI , CHE , ZNGA , WSO , NTRA ,

Endeavour Silver Corp. (NYSE:EXK) (TSE:EDR)s share price hit a new 52-week low during trading on Wednesday . The stock traded as low as $3.69 and last traded at $3.91, with a volume of 3664938 shares trading hands. The stock had previously closed at $3.90. Several equities research analysts have recently weighed in on EXK shares. []

Heritage Investors Management Corp grew its position in Exact Sciences Co. (NASDAQ:EXAS) by 17.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 96,046 shares of the medical research companys stock after purchasing an additional 14,047 shares during the period. []

Spire Wealth Management increased its stake in Exact Sciences Co. (NASDAQ:EXAS) by 9.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,728 shares of the medical research companys stock after buying an additional 234 shares during the quarter. Spire Wealth []

Westpac Banking Corp cut its stake in shares of Exact Sciences Co. (NASDAQ:EXAS) by 4.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 205,522 shares of the medical research company’s stock after selling 9,093 shares during the quarter. Westpac Banking Corp’s holdings in Exact Sciences were worth $19,617,000 at the end of […]

ARK Genomic ETF: Likely Economic Victim With Low Institutional Interest

Exact Sciences' (EXAS) recent study analysis validates that the Oncotype DX test helps identify early-stage, node-positive breast cancer who can avoid chemotherapy in most women.

Exact Sciences' (EXAS) recent study analysis validates that the Oncotype DX test helps identify early-stage, node-positive breast cancer who can avoid chemotherapy in most women.

Smart Beta ETF report for GSEW

- Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy MADISON, Wis., D

Koshinski Asset Management Inc. purchased a new position in shares of Exact Sciences Co. (NASDAQ:EXAS) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 490 shares of the medical research companys stock, valued at approximately $47,000. Other institutional investors and hedge funds have also recently []

Equities analysts predict that Exact Sciences Co. (NASDAQ:EXAS) will report earnings of ($0.87) per share for the current quarter, according to Zacks. Seven analysts have issued estimates for Exact Sciences earnings, with the highest EPS estimate coming in at ($0.42) and the lowest estimate coming in at ($1.17). Exact Sciences reported earnings per share of []

Exact Sciences Co. (NASDAQ:EXAS) has received a consensus recommendation of Buy from the fifteen ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price []